|
INTEGRIS Pharma is a fast-growing Greek pharmaceutical company.
|
About us
INTEGRIS Pharma was founded in 2008 as a CNS generics pharma. In 2018, the company successfully relaunched its business model, with a clear mission to cover the unmet therapeutic needs of patients with rare, chronic and life-threatening diseases in Greece and Cyprus, through innovative therapeutics.
Consistently serving this new strategic focus, INTEGRIS Pharma is actively seeking for innovative medicines throughout the world and is committed to ensure direct access for all patients, in the countries the company operates.
|
|
INTEGRIS Pharma is a fast-growing Greek pharmaceutical company.
|
|
|
About us
INTEGRIS Pharma was founded in 2008 as a CNS generics pharma. In 2018, the company successfully relaunched its business model, with a clear mission to cover the unmet therapeutic needs of patients with rare, chronic and life-threatening diseases in Greece and Cyprus, through innovative therapeutics.
Consistently serving this new strategic focus, INTEGRIS Pharma is actively seeking for innovative medicines throughout the world and is committed to ensure direct access for all patients, in the countries the company operates.
|
|
Within the last 5 years, INTEGRIS Pharma has entered into 13 new partnerships with leading, global biopharmaceutical companies and has built an extensive and diverse product portfolio for more than 17 diseases.
The company’s portfolio includes orphan drugs for rare and ultra-rare diseases, innovative pharmaceuticals complemented with hybrid and generic products in the fields of Oncology and Hematology as well as first-in-class medical devices for wound healing.
Recognizing the significant impact of these diseases on the lives of patients, their families, and caregivers, the company is committed to a comprehensive disease management from prevention to diagnosis, extending from product management that meets the highest quality and safety standards, to patient-centric initiatives that aim to address the needs of patients across their journey with the disease.
| Our mission | |
|
and values
Our mission is to address the unmet therapeutic needs of patients with rare, chronic and life-threatening diseases through innovative treatments. We serve the patients and stand by the healthcare professionals, with integrity, honesty and transparency. We build relationships and partnerships that are based on mutual trust. Not only within our corporate environment, but with all stakeholders that are involved or affected by our business activity. |
|
| Quality System | |
|
We ensure that the highest quality and safety standards are implemented in the management of our products. The Quality Management System of INTEGRIS Pharma supports the company’s processes for the import, distribution and sale of Pharmaceutical Products and the import, storage, distribution and sale of Medical Devices. The QMS meets the requirements of ISO 9001:2015, and is primarily focused on customer satisfaction and on the continuous improvement of processes, so us to ensure that we consistently provide products and services that meet customer and applicable statutory and regulatory requirements. As an integrated part of the Quality Management System, the company has established and implements an Anti-Bribery Management System which fully complies with the requirements of the ISO 37001:2016 standard, as certified by BQC. Additionally, the company has been certified by HTCert for Good Distribution Practice of Medical Devices and by CertiW® for compliance with the requirements of the ISO 13485:2016 Standard for the import, storage, distribution and sales of wound care medical devices.
|
|
| Disclosure of transfers of value to HCPs and HCOs | |
|
INTEGRIS PHARMA SA, following the national legislative framework, publicly announces on its official website its benefits to Healthcare Professionals and Healthcare Organizations. Through this disclosure, INTEGRIS ensures transparency in the company’s relations with the HCPs and HCOs, supporting the right of every patient to be informed of the interaction of INTEGRIS with the scientific community. Disclosure of transfers of value to HCPs and HCOs is available in the Greek section of the website. |
|
We value the power of our team and nurture the talent of our people. We work agilely and foster innovation, creativity and efficiency.
Read More